Can a Dual-Action diabetes drug prevent dangerous clots?
NCT ID NCT06618976
First seen Feb 15, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This completed study tested whether sotagliflozin, a dual SGLT1/2 inhibitor, reduces blood clot formation better than empagliflozin, a standard SGLT2 inhibitor. Seventeen healthy volunteers took each drug for one month in a crossover design. Researchers measured clot size and platelet activity in the lab to see if sotagliflozin offers extra protection against thrombosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sotagliflozin and Empagliflozin
What this could lead to
If sotagliflozin reduces clot formation more than empagliflozin, it could point toward a safer treatment option for heart patients at risk of blood clots.
What could go wrong
This was a very small study in 17 healthy people, not patients, so results may not apply to real-world heart disease. It only measured lab markers of clotting, not actual heart attacks or strokes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.